Relay Therapeutics Inc. Common Stock vs Williams Companies Inc — how do they compare? Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.94B), while Williams Companies Inc trades at $72.43 (market cap $87.41B). The key difference: Williams Companies Inc is far larger — about 22.2× Relay Therapeutics Inc. Common Stock's market cap, and Williams Companies Inc pays a 2.94% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 0 Days and Williams Companies Inc for 58 Days on average.
| RLAY | WMB | |
|---|---|---|
Market Cap | $3.94B | $87.41B |
Volume | 3,432,928 | 5,173,332 |
Sector | Health | Energy |
52-Week High | $20.75 | $79.40 |
52-Week Low | $6.03 | $56.51 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $3.06B | $118.03B |
Dividend Yield | — | 2.94% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Williams Companies (WMB) trades at $72.34, down 0.07% with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 25.18% net income margin and 24.02% ROE, supported by stable cash flows from operations of $5.90B. Recent earnings show mixed results with Q1 2026 beating expectations while Q2 2026 slightly missed. The company benefits from growing natural gas demand driven by AI data center expansion and maintains a strategic position in midstream energy infrastructure.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus price target offering 21% upside. Key opportunities include dividend growth strategy and exposure to AI-powered energy demand, while risks involve energy market volatility and high debt levels of $24.74B long-term debt. The stock's valuation at 28.47 P/E appears justified by strong profitability and growth prospects in natural gas infrastructure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →